Posted in | News | Nanomedicine

NanoActive Formulation Boosts Oral Bioavailability of Drugs, Shows In Vivo Data

NanGenex Inc., the proprietary NanoActive™ continuous flow technology platform company, has completed the first round in vivo testing of NanoActive™ nanoformulations of block-buster drugs.

Low water solubility and/or dissolution rate is the rate limiting step of oral absorption and bioavailability of several marked drugs including several angiotensin II receptor antagonists used in the treatment of hypertension. Using the NanoActive™ technology NanGenex has managed to increase the water solubility of three such drug compounds that are widely used in clinical practice. Laboratory tests showed a 10-1000 fold increase in water solubility for the different compounds. Furthermore, the redispersibility and dissolution of the compounds in biological relevant medium was practically instantaneous in these tests.

In order to assess whether improvement in solubility and dissolution rate results in increased oral absorption and bioavailability animal studies using Sprague-Dawley rats and beagle dogs were performed. For all three compounds there was a significant (2-7 fold) increase in bioavailability after oral administration of the NanoActive™ formulation when compared to administration of the referencecompound via the same route. Moreover, maximal blood concentrations were detected earlier following administration (30-45 minutes for the NanoActive™ formulations, 120 minutes for the reference compounds) indicating faster oral absorption of the NanoActive™ formulations.

The obtained in vivo data clearly show that the NanoActive™ technology successfully increase the oral bioavailability of poorly water soluble drugs. Using the new formulations the same therapeutic blood concentrations can be achieved by administering significantly lower drug doses. Furthermore, instantaneous release of the drug from the formulation could result in faster onset of action for compounds where dissolution is the rate limiting step of oral absorption.

Source: http://www.nangenex.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Tavanta Therapeutics. (2019, February 13). NanoActive Formulation Boosts Oral Bioavailability of Drugs, Shows In Vivo Data. AZoNano. Retrieved on December 07, 2024 from https://www.azonano.com/news.aspx?newsID=18758.

  • MLA

    Tavanta Therapeutics. "NanoActive Formulation Boosts Oral Bioavailability of Drugs, Shows In Vivo Data". AZoNano. 07 December 2024. <https://www.azonano.com/news.aspx?newsID=18758>.

  • Chicago

    Tavanta Therapeutics. "NanoActive Formulation Boosts Oral Bioavailability of Drugs, Shows In Vivo Data". AZoNano. https://www.azonano.com/news.aspx?newsID=18758. (accessed December 07, 2024).

  • Harvard

    Tavanta Therapeutics. 2019. NanoActive Formulation Boosts Oral Bioavailability of Drugs, Shows In Vivo Data. AZoNano, viewed 07 December 2024, https://www.azonano.com/news.aspx?newsID=18758.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.